PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Positioned as Early Entrant in Rapidly Growing Field of Psychedelics

UC Berkeley and other prominent academic institutions, including Johns Hopkins University in Maryland and Imperial College in London, are accelerating scientific research of psilocybin by launching a new center focusing on the compound (https://ibn.fm/VdvfN). Cybin (NEO: CYBN), a mushroom life science company, is positioned amid this growing research interest that is bringing psilocybin into mainstream. A recent article discussing the company reads, “Dedicated to supporting clinical studies across North America and other regions through strategic academic and institutional partnerships, including the Canadian Centre for Psychedelic Science, Cybin is poised to benefit from the increasing research interest in psilocybin. As an early entrant into a rapidly growing field, Cybin seems well positioned to leverage the growing recognition of psychedelic research leading to eventual public acceptance with the potential to propel the whole industry to the new level.”

To view the full article, visit https://ibn.fm/E4pDG

About Cybin Inc.

Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems aiming to improve bioavailability to achieve the desired effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.